FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2065-2067 November 20, 2003 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group PubMed Citation

Soon after the introduction of protease inhibitors and nonnucleoside reverse-transcriptase inhibitors for the management of human immunodeficiency virus (HIV) infection, clinicians observed unexpected cardiovascular events among patients receiving these new, combination, "highly active" antiretroviral regimens. Angina, myocardial infarction, and stroke were seen in patients who were relatively young. Providers became suspicious that these events were related either to chronic HIV infection, since patients were surviving for longer periods than they had in the past, or to the new anti-HIV regimens, which are associated with substantial metabolic abnormalities.

Between 1998 and 2003, several reports appeared to validate clinicians' concerns. The French . . . [Full Text of this Article]

Source Information

From the Division of HIV/AIDS Medicine, Drexel University College of Medicine, Philadelphia (P.S.); and the Critical Care Medicine Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Md. (H.M.).

This article has been cited by other articles:

• Hsue, P. Y., Squires, K., Bolger, A. F., Capili, B., Mensah, G. A., Temesgen, Z., Wanke, C. A., Wohl, D. A., for Working Group 4, (2008). Screening and Assessment of Coronary Heart Disease in HIV-Infected Patients. Circulation 118: e41-e47 [Full Text]  
• Blanco, J. J. R., Garcia, I. S., Cerezo, J. G., de Rivera, J. M. P. S., Anaya, P. M., Raya, P. G., Garcia, J. G., Lopez, J. R. A., Hernandez, F. J. B., Rodriguez, J. J. V. (2006). Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother 58: 133-139 [Abstract] [Full Text]  
• Qureshi, A I (2005). HIV infection and stroke: if not protein S deficiency then what explains the relationship?. J. Neurol. Neurosurg. Psychiatry 76: 1331-1331 [Full Text]  
• Zhou, H., Pandak, W. M. Jr., Lyall, V., Natarajan, R., Hylemon, P. B. (2005). HIV Protease Inhibitors Activate the Unfolded Protein Response in Macrophages: Implication for Atherosclerosis and Cardiovascular Disease. Mol. Pharmacol. 68: 690-700 [Abstract] [Full Text]  
• Latham, V., Stebbing, J., Mandalia, S., Michailidis, C., Davies, E., Bower, M., Gazzard, B., Nelson, M. (2005). Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J Antimicrob Chemother 56: 186-189 [Abstract] [Full Text]  
• Yach, D., Hawkes, C., Gould, C. L., Hofman, K. J. (2004). The Global Burden of Chronic Diseases: Overcoming Impediments to Prevention and Control. JAMA 291: 2616-2622 [Abstract] [Full Text]  
• (2003). Antiretrovirals Appear to Increase MI Risk. JWatch General 2003: 3-3 [Full Text]